Soft Tissue Roasi-Dorfman Disease with Features of IgG4-Related Disease in a Patient with a History of Acute Myeloid Leukemia

Park, Cheol Keun; Kim, Min Jung; Kim, Jee Ye; Woo, Ha-Young; Jang, Mi; Jeong, Hyang Sook; Yang, Woo Ick; Kim, Sang Kyum

doi:10.4132/jptm.2015.10.08

Cited by 1 publication

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, in the IgG4-associated classical RDD, a polyclonal proliferation of IgG4 positive plasma cells and high levels of plasma IG4 levels are observed [158]. This is possibly representing a continuum of RDD to the recently defined nosological entity of IgG4-related disease, which is a chronic immune-mediated fibro-inflammatory condition involving multiple organs, like exocrine and endocrine glands, orbit, retroperitoneum [30,63,158].…”

Section: Igg4-associated Classical Rddmentioning

confidence: 94%

See 1 more Smart Citation

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

2016

View full text Add to dashboard Cite

Rare histiocytoses, also called non-Langerhans cell histiocytoses, include all proliferative disorders of histiocytes, macrophages and dendritic cells that are not classified as Langerhans cell histiocytosis (LCH) and do not belong to the hemophagocytic lymphohistiocytosis (HLH) group of diseases. Thus, the term includes numerous benign or malignant, localized or systemic, adult or pediatric diseases. The classification of the histiocytic disorders has been revised several times. Here, we follow the classification recently published by Jean Francois Emile and an international expert panel, defining subgroups of histiocytoses described as L-Group, C-Group, M-Group, R-Group, and H-Group, which stands for LCH-like, cutaneous or mucocutaneous, malignant, Rosai-Dorfman-Disease like and HLH like. Some of the diseases have an excellent prognosis after resection or even disappear spontanously, others progress rapidly, requiring intensive systemic therapies. The malignant non-Langerhans cell histiocytoses in general have a poor prognosis, here, complex chemotherapy protocols are usually applied, with inconsistant results. An interesting perspective in non-malignant rare histiocytoses might be small molecular inhibitors, in particular BRAF inhibitors, since BRAF mutations have been found in some subtypes of non-Langerhans cell histiocytoses. By prospective and retrospective collection of experiences in a new registry (the "International Rare Histiocytic Disorders Registry", IRHDR), knowledge about these rare diseases might hopefully be improved.

show abstract

Section: Igg4-associated Classical Rddmentioning

confidence: 94%

“…So, RDD post leukemia (4.4.1.) [158] or RDD post lymphoma (4.4.2.) [75], RDD associated with malignant histiocytosis (4.4.3.)…”

Section: Neoplasia-associated Rddmentioning

confidence: 99%

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

2016

View full text Add to dashboard Cite

show abstract

Soft Tissue Roasi-Dorfman Disease with Features of IgG4-Related Disease in a Patient with a History of Acute Myeloid Leukemia

Cited by 1 publication

References 10 publications

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

The Non-Langerhans Cell Histiocytoses (Rare Histiocytoses) – Clinical Aspects and Therapeutic Approaches

Contact Info

Product

Resources

About